Citation Impact
Citing Papers
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
2014 Standout
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
2016
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
2013 StandoutNobel
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
2015
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
2013
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Cancer statistics, 2020
2020 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
2013
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
The microbiota in adaptive immune homeostasis and disease
2016 StandoutNature
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
The Human Intestinal Microbiome in Health and Disease
2016 Standout
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
2017
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
2014
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
2013
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
2017
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
2015
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
2018
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
2013
Immune checkpoint modulation: Rational design of combination strategies
2015
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Radiotherapy: Changing the Game in Immunotherapy
2016
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
2017
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
2016
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
The PI3K Pathway in Human Disease
2017 Standout
Migrating into the Tumor: a Roadmap for T Cells
2017
Gene-expression profiling to predict responsiveness to immunotherapy
2016
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
2014
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer
2013
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
2012 Standout
Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8 + T cells
2016
Hepatocellular Carcinoma
2019 Standout
Coinhibitory Pathways in Immunotherapy for Cancer
2016
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
Innate immune sensing of cancer: clues from an identified role for type I IFNs
2012
Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells
2017
Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?
2017
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
2016
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Innate Immune Recognition of Cancer
2015
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
2013
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
2016
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
2018 StandoutScience
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal
2014 Standout
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
2014 StandoutNobel
Neoantigens in cancer immunotherapy
2015 StandoutScience
The host STING pathway at the interface of cancer and immunity
2016
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
2013 Standout
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
2013
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
2014
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Works of Lisu Wang being referenced
Lipid peroxidation end product 4-hydroxy-trans-2-nonenal triggers unfolded protein response and heme oxygenase-1 expression in PC12 cells: Roles of ROS and MAPK pathways
2013
An immune-active tumor microenvironment favors clinical response to ipilimumab
2011
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
2013
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-mediate gastrointestinal adverse events.
2012